Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany

International Journal of Medical Microbiology

Volumn 305, Issue 7, 2015, Pages 776-783

  Imöhl, Matthias ^a   Reinert, Ralf René ^b   van der Linden, Mark ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b PFIZER INC   (United States)

Author keywords

Antimicrobial susceptibility; Germany; Invasive disease; Streptococcus pneumoniae; Vaccine

Indexed keywords

CEFOTAXIME; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; PENICILLIN V; PNEUMOCOCCUS VACCINE; TETRACYCLINE; ANTIINFECTIVE AGENT; VACCINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PENICILLIN RESISTANCE; PHENOTYPE; PNEUMOCOCCAL MENINGITIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; AGED; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; INFANT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; PREVALENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; FEMALE; GERMANY; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREVALENCE; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84944277076     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2015.08.031     Document Type: Article

References (33)

1. Austrian R. Pneumococcus: the first one hundred years. Rev. Infect. Dis. 1981, 3:183-189.
2. Beekmann S.E., Heilmann K.P., Richter S.S., Garcia-de-Lomas J., Doern G.V. Antimicrobial resistance in streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis and group a beta-haemolytic streptococci in 2002-2003. Results of the multinational grasp surveillance program. Int. J. Antimicrob. Agents 2005, 25:148-156.
3. Ben-Shimol S., Greenberg D., Givon-Lavi N., et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine 2014, 32:3452-3459.
4. Bley C., van der Linden M., Reinert R.R. Mef(a) is the predominant macrolide resistance determinant in Streptococcus pneumoniae and Streptococcus pyogenes in Germany. Int. J. Antimicrob. Agents 2011, 37:425-431.
5. Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement 2006, Wayne, PA.
6. Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement 2008, Wayne, PA.
7. Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement 2014, Wayne, PA.
8. Dagan R., Klugman K.P. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect. Dis. 2008, 8:785-795.
9. EUCAST Breakpoint tables for interpretation of MICs and zone diameters 2009, European Society of Clinical Microbiology and Infectious Diseases. http://www.eucast.org/.
10. EUCAST Breakpoint tables for interpretation of MICs and zone diameters 2014, European Society of Clinical Microbiology and Infectious Diseases. http://www.eucast.org/.
11. Feikin D.R., Klugman K.P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis. 2002, 35:547-555.
12. Feikin D.R., Klugman K.P., Facklam R.R., Zell E.R., Schuchat A., Whitney C.G. Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin. Infect. Dis. 2005, 41:481-487.
13. Fenoll A., Granizo J.J., Aguilar L., et al. Temporal trends of invasive streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J. Clin. Microbiol. 2009, 47:1012-1020.
14. Giovanetti E., Montanari M.P., Mingoia M., Varaldo P.E. Phenotypes and genotypes of erythromycin-resistant streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains. Antimicrob. Agents Chemother. 1999, 43:1935-1940.
15. Goossens M.C., Catry B., Verhaegen J. Antimicrobial resistance to benzylpenicillin in invasive pneumococcal disease in Belgium, 2003-2010: the effect of altering clinical breakpoints. Epidemiol. Infect. 2013, 141:490-495.
16. Grabenstein J.D., Weber D.J. Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake. Clin. Infect. Dis. 2014, 58:854-864.
17. Hammitt L.L., Bruden D.L., Butler J.C., et al. Indirect effect of conjugate vaccine on adult carriage of streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J. Infect. Dis. 2006, 193:1487-1494.
18. Imöhl M., Reinert R.R., van der Linden M. New penicillin susceptibility breakpoints for Streptococcus pneumoniae and their effects on susceptibility categorisation in Germany (1992-2008). Int. J. Antimicrob. Agents 2009, 34:271-273.
19. Imöhl M., Reinert R.R., van der Linden M. Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states. Int. J. Med. Microbiol. 2009, 300:237-247.
20. Imöhl M., Reinert R.R., van der Linden M. Temporal variations among invasive pneumococcal disease serotypes in children and adults in Germany (1992-2008). Int. J. Microbiol. 2010, 2010:874189.
21. Imöhl M., Reinert R.R., Tulkens P.M., van der Linden M. Penicillin susceptibility breakpoints for streptococcus pneumoniae and their effect on susceptibility categorisation in Germany (1997-2013). Eur. J. Clin. Microbiol. Infect. Dis. 2014.
22. Imöhl M., Möller J., Reinert R.R., Perniciaro S., van der Linden M., Aktas O. Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany. BMC Infect. Dis. 2015, 15:61.
23. Jacobs M.R., Good C.E., Beall B., Bajaksouzian S., Windau A.R., Whitney C.G. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J. Clin. Microbiol. 2008, 46:982-990.
24. Kyaw M.H., Lynfield R., Schaffner W., et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant streptococcus pneumoniae. N. Engl. J. Med. 2006, 354:1455-1463.
25. Lai C.C., Lin S.H., Liao C.H., Sheng W.H., Hsueh P.R. Decline in the incidence of invasive pneumococcal disease at a medical center in Taiwan, 2000-2012. BMC Infect. Dis. 2014, 14:76.
26. Livermore D.M. Bacterial resistance: origins, epidemiology, and impact. Clin. Infect. Dis. 2003, 36:S11-S23.
27. Mokaddas E., Albert M.J. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of streptococcus pneumoniae isolates: an overview from Kuwait. Vaccine 2012, 30(Suppl. 6):G37-G40.
28. Musher D.M. Infections caused by streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin. Infect. Dis. 1992, 14:801-807.
29. Perez-Trallero E., Martin-Herrero J.E., Mazon A., et al. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). Antimicrob. Agents Chemother. 2010, 54:2953-2959.
30. Regev-Yochay G., Rahav G., Riesenberg K., et al. Initial effects of the national pcv7 childhood immunization program on adult invasive pneumococcal disease in Israel. PLoS ONE 2014, 9:e88406.
31. Reinert R.R. Pneumococcal conjugate vaccines - a European perspective. Int. J. Med. Microbiol. 2004, 294:277-294.
32. Su L.H., Wu T.L., Kuo A.J., Chia J.H., Chiu C.H. Antimicrobial susceptibility of streptococcus pneumoniae at a university hospital in Taiwan, 2000-07: impact of modified non-meningeal penicillin breakpoints in CLSI m100-s18. J. Antimicrob. Chemother. 2009, 64:336-342.
33. Weil-Olivier C., van der Linden M., de Schutter I., Dagan R., Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect. Dis. 2012, 12:207.